Stroke patient volume and diagnoses
| 2019 n=333 | COVID-19 n=304 | P | |
| Patients/day, median (IQR) | 4 (2, 5) | 3 (2, 5) | 0.21 |
| Age, median (IQR) | 70 (60, 80) | 70 (60, 80) | 0.64 |
| Sex, % male (n) | 57% (191) | 45% (137) | 0.002 |
| Race, % white (n) | 66% (219) | 70% (213) | 0.26 |
| Transfer, % (n) | 24% (81) | 23% (70) | 0.72 |
| Comorbidity count, median (IQR) | |||
| Ischemic stroke, % (n) | 77% (255) | 78% (236) | 0.69 |
| Hemorrhagic stroke, % (n) | 16% (54) | 19% (57) | 0.39 |
| TIA, % (n) | 11% (38) | 8% (23) | 0.10 |
| Time from onset to arrival, minutes, median (IQR) | 273 (132, 571) | 263 (115, 532) | 0.46 |
| Ischemic stroke treatment | |||
| Door to needle time, minutes, median (IQR) | 14 (11, 22) | 22 (13, 29) | 0.12 |
| tPA prior to arrival, % (n) | 18% (45) | 18% (41) | 0.89 |
| IV tPA treatment on arrival, % (n) | 6% (16) | 7% (17) | 0.85 |
| Treated with endovascular therapy, % (n) | 22% (55) | 25% (57) | 0.54 |
IQR, Interquartile range; IV, intravenous; RCVS, reversible cerebral vasoconstriction syndrome; TIA, transient ischemic stroke; tPA, tissue plasminogen activitor.